http___bg.gsk.com_bg-bg__D0_B7_D0_B0-_D0_BD_D0_B0_D1_81__2.xml
1.1 2.1 2.2 3.1 3.2 4.1 5.1 6.1 7.1 8.1 9.1 10.1 11.1 12.1 13.1 14.1 14.2 15.1
За нас Ние сме глобална фармацевтична компания, водена от науката. Нашата мисия е да помагаме на хората да правят повече, да се чувстват по-добре, да живеят по-дълго. Днес все още има милиони хора, които нямат достъп до базисно здравеопазване, хиляди болести, за които няма адекватно лечение и милиони хора, които ежедневно страдат от различни заболявания. Ние в GSK искаме да променим това. Развиваме три водещи световни бизнеса, които изследват, разработват и произвеждат иновативни фармацевтични лекарства, ваксини и лекарства без рецепта. Отдадени сме на това да разширяваме достъпа до нашите продукти, така че повече хора да имат достъп до тях, независимо в коя точка на света живеят и дали могат да си ги позволят. Вижте всички наши ключови постижения Като глобална компания в здравеопазването, ние поемаме някои от най-големите световни предизвикателства, свързани със здравеопазването. Чрез предоставяне на устойчив бизнес, ние предлагаме ползи за здравето на пациентите и потребителите и подкрепа на обществото като цяло. Всяко от нашите три бизнес направления използва търговската ни инфраструктура, интегрираните мрежи за доставка и значителното глобално присъствие на компанията. Ние в GSK вярваме, че начинът, по който правим бизнес е също толкова важен, колкото и това какво правим - това е, което прави разлика - ние предизвикваме установените норми в индустрията като променяме начина си на работа. Нашата история Хронология на нашата история – На пазара се появява марката Beecham’s Pills Томас Бийчъм стартира бизнеса с Beecham’s Pills в Англия. Лаксативът става успешен в цял свят. Вижте цялата хронология на нашата история.
1.1 2.1 5.1 8.1 11.1 12.1 13.1 14.1 15.1 16.1 16.2 17.1 18.1 19.1 20.1 21.1 22.1 23.1 23.2 24.1 25.1 26.1 27.1 28.1 29.1 30.1 31.1 31.2 32.1 33.1 34.1 35.1 36.1 37.1 38.1 39.1 42.1 45.1 48.1 49.1 50.1 53.1 56.1 59.1 61.1 62.1 63.1 64.1 64.2 67.1 70.1 71.1 72.1 73.1 76.1 79.1 82.1 83.1 85.1 86.1 88.1 89.1 91.1 92.1 92.2 94.1 95.1
About GSK We are a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer. Group turnover in 2021 global businesses years of innovation What we do We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, preventing and treating disease and keeping people well with our scientific and technical know-how and talented people. Pharmaceuticals £17.7bn, +10% CER sales turnover 2021 Our Pharmaceuticals business has a broad portfolio of innovative and established medicines in respiratory, HIV, immuno-inflammation and oncology. We are strengthening our R&D pipeline through a focus on immunology, human genetics and advanced technologies to help us deliver transformational new medicines for patients. Key products Trelegy – Asthma/COPD Nucala – Severe Asthma Triumeq/Tivicay – HIV Vaccines £6.8bn, +2% CER sales turnover 2021 We are the world’s largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life. Our R&D focuses on developing vaccines against infectious diseases that combine high medical need and strong market potential. Key products Shingrix – Shingles Infanrix – Paediatric Bexsero – Meningitis Consumer Healthcare £9.6bn, stable CER sales turnover 2021 (+4% excluding brands divested/under review) Our world-leading Consumer Healthcare business combines science and consumer insights to create innovative everyday healthcare brands that consumers trust and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements. In early 2020, we started a two-year programme to prepare GSK for separation into two new, exciting companies - a new GSK in Biopharma and a new world leader in Consumer Healthcare. We remain on track to separate in 2022. Key products Sensodyne – Oral health Voltaren – Pain relief (topical) Panadol – Pain relief (systemic) How we do it Everyone at GSK is focused on our three long-term priorities - Innovation, Performance, Trust - underpinned by our ambition to build a more purpose and performance driven culture, aligned to our values. Innovation We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers. adjusted R&D investment in 2021 new medicines in development at FY 2021 new vaccines in development at FY 2021 Performance We deliver growth by investing effectively in our business, developing our people and executing competitively. Group turnover in 2021 adjusted operating profit in 2021 free cash flow in 2021 £4bn dividends paid in 2021 Trust We are a responsible company. We commit to use our science and technology to address health needs, make our products affordable and available and be a modern employer. employee engagement score on our latest employee survey in Access to Medicines Index since the assessment began in 2008 Key figures Please refer to our quarterly results materials for further information on GSK’s financial performance. Our geographies US (+6% CER) sales turnover 2020 Europe (+1% CER) sales turnover 2020 International (flat CER) sales turnover 2020 Find out more about us Quarterly results Discover our latest financial performance announcement and search for historical quarterly results materials Speeches & presentations Search through our archive of speeches and presentations from conferences and events Our history It began when Plough Court Pharmacy was established in 1715. Discover GSK's journey that led to the organisation we know today Our pipeline We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers